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Renal Ultrastructural and Biochemical
Injuries Induced by Aminoglycosides
by Constantin Cojocel,* N. Docius,t Keizo Maita,*
Jacqueline H. Smith* and Jerry B. Hook*
Aminoglycoside-induced proteinuria may result from general renal damage or may reflect alterations in
specific steps in the renal handling ofproteins. To differentiate between the two possibilities, experiments
were designed to quantify the effects ofnephrotoxic doses ofgentamicin, tobramycin and netilmicin in the
intact rat, isolated perfused rat kidney (IPK) and kidney slices using the cationic low molecular weight
protein lysozyme as a model protein. Each aminoglycoside was administered IP to male Wistar rats (15 or
30 mg/kg/day) for 5 or 7 days.
Scanning and transmission electron microscopy indicated that gentamicin and tobramycin induced a
decrease in the numberanddiameter ofendothelial fenestrae and degranulation ofthe myoepithelioid cells
of the juxtaglomerular apparatus. Concurrently, gentamicin and tobramycin decreased the glomerular
sieving coefficient oflysozyme from 0.8 to 0.6 and 0.5, respectively. Netilmicin did not affect the percentage
reabsorption of lysozyme whereas gentamicin and tobramycin induced a 50% decrease in lysozyme
reabsorption by the IPK. Gentamicin and tobramycin decreased equally lysozyme degradation by the IPK;
this decrease was time- and dose-dependent when evaluated in slices from renal cortex. Perfusion of rat
kidneys with gentamicin induced a dose-dependent decrease in reabsorption and catabolism of lysozyme.
In conclusion, these studies demonstrate that polycationic aminoglycosides alter ultrastructure and
glomerular permeability, tubular reabsorption and intracellular digestion of proteins.
Aminoglycoside antibiotics are valuable therapeutic
agents which are employed frequently in clinical
management of gram-negative bacterial infections.
Nephrotoxicity, a major side effect of aminoglycoside
treatment, is usually characterized by a fall in glo-
merular filtration rate (GFR), decreased urinary
concentrating capacity, proteinuria, enzymuria and
ultrastructural alteration of proximal tubular cells.
For several years, efforts of various research groups
have focused on detection and assessment of the
mechanisms ofaminoglycoside nephrotoxicity. Luminal
uptake is the major route of aminoglycoside tubular
reabsorption and subsequent intracellular accumula-
tion (1-3). Contraluminal uptake of aminoglycosides
(4,5) also appears to contribrute to the accumulation
of aminoglycosides. Although aminoglycosides inhibit
Na, K-ATPase activity, it is unlikely that this is the
primary mechanism of aminoglycoside nephrotoxicity
(6). The effects of aminoglycosides on mitochondrial,
(7) and lysosomal function (8-11) appear to play the
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main role in aminoglycoside-induced nephrotoxicity.
There is new evidence to support glomerular altera-
tions induced by aminoglycosides (8), though this is
still disputed (12-14). Low molecular weight proteins
(LMWP) are well filtered by the glomerulus and
almost totally reabsorbed by the tubule in control
conditions. Renal handling of LMWP such as lyso-
zyme and P2-microglobulin appears to be an early
target in aminoglycoside nephrotoxicity (15,16). A
summary of some of our investigations on the effects
of aminoglycosides on renal filtration, reabsorption
and catabolism of proteins are presented herein.
Glomerular Alterations
Decreased GFR is a common finding in patients and
experimental animals treated with aminoglycosides.
Ireatment ofmale rats with a toxic dose (30 mg/kg/day)
of aminoglycosides for 7, 14 and 21 days (Fig. 1)
demonstrated that only gentamicin and netilmicin
decreased GFR over the entire treatment period. The
same in vivo experiments indicate that tobramycin
failed to decrease GFR. After 14 days of treatment
GFR showed a tendency to return to control in rats
treated with netilmicin. No recovery of GFR was
observed in gentamicin-treated rats. Gentamicin
treatment ofMunich-Wistar rats for 10 days at a similarCOJOCEL ET AL.
dose (40 mg/kg/day) also induced a significant decrease
in glomerular capillary ultrafiltration coefficient (I(f)
(12).
Since aminoglycoside treatment appeared to decrease
tubularreabsorption ofthelowmolecularweightprotein
lysozyme, investigation ofthe effects ofaminoglycosides
on glomerular filtration ofthis protein was necessary to
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FIGURE 1. Effects ofaminoglycosides on GFR in intact rats. Days =
duration of aminoglycoside treatment, n = number of clearance
periods. Significantly different from control (p s 0.05). Bars
represent mean ± 1 SD. From Cojocel and Hook (15). Reprinted
with permission of Elsevier Scientific Publishers, Ireland, Ltd.
elucidate the mechanism by which aminoglycosides
alter its renal reabsorption and catabolism. Thus,
experiments with the isolated perfused kidney were
designed to determine the glomerular sievingcoefficient
of lysozyme. At complete inhibition of tubular
reabsorption of lysozyme the ratio of lysozyme
clearance/inulin clearance (CLy/GFR) expresses the
glomerular sieving coefficient of lysozyme (GSCLY).
Followingaminoglycosidetreatment, sodiumiodoacetate
was added to the perfusate (3-5 mM) to completely
inhibit tubular reabsorption of lysozyme (17). Amino-
glycoside treatment decreased the GSCLY from a
control value of 0.8 to 0.6 and 0.5 in kidneys from
Table 1. Effect of aminoglycosides on the density
of endothelial fenestrae (EF).
Treatment EF density (25 cm2)a % of Control
Saline (Control) 99 ± 2 (n = 4) 100
Netilmicin 103 ± 2 (n = 4) 100
Gentamicin 82 ± 3* (n = 5) 82*
Tobramycin 77 ± 3* (n = 5) 77*
aThe density of endothelial fenestrae was determined by counting
the number of fenestrae on a 25 cm2 area of prints from scanning
electron microscopy. Each aminoglycoside was administered at a dose
of 30 mg/kg/day for 7 days. Data are given as means X ± SD.
Numbers in parentheses represent the number of rats.
*Significantly different from control value (p < 0.05).
FIGURE 2. Glomerular ultrastructure by scanning electron microscopy. Scanning electron micrograph showing endothelial fenestrae (arrow) in
control rats. Cytoplasmic ridges (CR) are noticeable. x28,000. From Cojocel et al. (8). Reprinted with permission of Academic Press.
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FIGURE 3. Effect of gentamicin on glomerular ultrastructure. Iransmission electron micrograph of the afferent arteriole ofjuxtamedullary
apparatus from (a) control and (b) gentamicin-treated rats for 7 days (30 mg/kg/day). Myoepithelioid cells (ME) contain numerous electron
dense cytoplasmic granules (arrows) in control rats while these granules are almost completely depleted in gentamicin-treated rats. x 5470.
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gentamicin-and tobramycin-treated rats, respectively;
netilmicin had no effect. Scanning and transmission
electron microscopy indicated that gentamicin and
tobramycin altered the ultrastructure ofthe glomerular
endothelium by reducing diameter and frequency of
endothelial fenestrae (Fig. 2 and Table 1). Quantitative
morphometric studies usingdatafrom scanningelectron
microscopy (Table 1) supported previous studies (18)
and demonstrate that aminoglycoside treatment de-
creased the number ofglomerular capillary endothelial
fenestratrae.
Glomerular functional and ultrastructural alterations
caused by aminoglycoside treatment could be induced
through a tubuloglomerular feedback mechanism
mediated by the renin-angiotensin system which has
been suggested to be related to the pathogenesis of
acute renal failure by Thurau et al. (19). Consistent with
this hypothesis, high doses of gentamicin (120
mg/kg/day) produced a significant increase in plasma
renin activity and a concurrent decrease in GFR in rats
(20). Lower doses of gentamicin or tobramycin (30
mg/kg/day) induced an almost complete depletion of
cytoplasmic granules from the myoepitheliod cells in the
afferent arterial wall ofthejuxtamedullar apparatus as
revealed by transmission electron microscopy (Fig. 3).
At the same dose, depletion of cytoplasmic granules
was less severe in netilmicin-treated rats. However, in
these studies, there was no disintegration of the
granules, elevated exocytotoxic excretion processes, or
activation of rough endoplasmic reticulum. Thus, it is
uncertain whether the depletion of the cytoplasmic
granules from the myoepithelioid cells after amino-
glycoside treatment was related to activation of the
renin-angiotensin system. The precise role played by
this system in aminoglycoside-induced renal failure
remains to be clarified by further studies.
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FIGURE 4. Effects of aminoglycosides on electrolyte excretion in
intact rats. Excretion of sodium and potassium in control and
aminoglycoside-treated rats for 7 days (30 mg/kg/day). C =
control, G = gentamicin, K = kanamycin, N = netilmicin. From
Cojocel and Hook (33). Reprinted with permission of Elsevier
Science Publishers, B. V, Amsterdam.
Impairment of Tubular Reabsorption
Treatment of patients or experimental animals with
aminoglycoside antibiotics results in tubular cell injury
and necrosis accompanied by enhanced excretion of
glucose (21) or of LMWP such as 132-microglobulin (16).
These functional alterations suggest an impairment of
tubularreabsorptive capacity. Indeed, increasedurinary
excretion of sodium and potassium are found in
aminoglycoside-treated rats (Fig. 4). In these experi-
ments gentamicin appeared to have a much more
pronounced effect than netilmicin. The specific mech-
anism by which aminoglycosides decrease tubular
reabsorption of electrolytes is still unknown.
Aminoglycoside treatment leads to an increased
excretion of brush border enzymes (22), lysosomal
enzymes (23) and LMWP such as P2-microglobulin and
lysozyme (16). Aminoglycoside-induced functional
alterations were detected by measuring the urinary
excretion ofthe LMWPlysozyme, thelysosomalenzyme
N-acetyl-,3-D-glucosaminidase and total proteins in
intact rats (Table 2). Gentamicin was more potent
than netilmicin in decreasing tubular reabsorption of
lysozyme and induced damage to cellular membranes
causing leakage of the lysosomal marker enzyme NAG
and an increase in total protein excretion (Table 2).
Thbular reabsoption of lysozyme had a tendency to
return toward control despite continued administration
ofgentamicin or tobramycin (15). Determination of the
glomerular sieving coefficient of lysozyme after amino-
glycoside treatment allowed a more accurate quantita-
tion of tubular reabsorption of lysozyme (Table 3).
Gentamicin and tobramycin (30 mg/kg/day) decreased
endocytic reabsorption oflysozyme in isolated perfused
kidneys to about 50% after 7 days of treatment. Since
aminoglycosides and lysozyme are taken up into tubular
Table 2. Daily urinary excretion of endogenous lysozyme (LY),
N-acetyl-4-D-glucosaminidase (NAG) and total protein (P)
in aminoglycoside-treated rats.
Control Netilmicin Gentamicin
Ly, jig/day 4.72 ± 0.50 5.95 ± 1.42 31.79 ± 18.99
NAG, ,umole/
hr/day 0.79 ± 0.08 0.78 ± 0.26 3.32 ± 1.76
P mg/day 6.22 ± 1.10 6.39 ± 0.38 38.3 ± 9.64
aAll experimental data are given as mean value ± SD. Each
experimental group consisted of five rats. Each aminoglycoside was
administered at a dose of 30 mg/kg/day for 7 days.
*Data are significantly different from control (p < 0.05).
Table 3. Effect of aminoglycosides on renal reabsorption of
lysozyme by the isolated perfused rat kidney.
Control Netilmicin Gentamicin Tobramicin
X ± SD 71.7 ± 3.0 69.7 ± 3.5 35.4 ± 6.8 32.4 ± 10.5
n 5 6 5 5
aEach aminoglycoside was administered at a dose of 30mg/kg/day
for 7 days. Lysozyme reabsorption is expressed as % of filtered
load. n = number of kidneys.
*Significantly different from control (p < 0.05).
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cells by endocytosis, it is very likely thatthe differential
effects of aminoglycosides on tubular reabsorption of
lysozyme represent specific alterations in proximal
tubular function such as impairment of the endocytic
protein reabsorption.
Decrease of Lysosomal Proteolysis
Protein degradation in the kidney occurs mainly in
lysosomes, organelles that are known to accumulate
nephrotoxicants such as aminoglycosides. Gentamicin
labilizes the lysosomal membrane causing increased
release of lysosomal marker enzymes to the incubation
medium in vitro (24) and increased excretion of
lysosomal enzymes in vivo (25). Likewise, gentamicin
treatment ofrats led to a decrease oflysosomal protein
degradation by renal cortical slices in a dose-related
fashion (26) (Fig. 5). In these studies, the effects of
gentamicin on lysosomal degradation of lysozyme by
renal cortical slices was measured as free (nonpre-
cipitable)radioactivity and wasexpressed aspercentage
oftotal radioactivity released tothe incubation medium.
The effects ofgentamicin, tobramycin and netilmicin on
renal protein degradation were compared (Fig. 6) in the
isolated perfused rat kidney (8). In these studies
GENTAMICIN
*-@ Control
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A.. 3mg,5d
lysozyme degradation was estimated by the release of
tyrosine into the perfusate during a 150-min perfusion
period. TEyrosine concentration in the perfusate was
quantified by high-pressure liquid chromatography
(HPLC). The more nephrotoxic aminoglycosides, genta-
micin and tobramycin, significantly decreased the
release of tyrosine to the perfusate from a control
value of 12.0 to approximately 4.5 ,umole. Netilmicin
appeared to have no effect on renal degradation of
lysozyme (Fig. 6). This study also showed that gentami-
cin and tobramycin had similar effects on renal protein
catabolism. The decrease in renal catabolism of lyso-
zyme may be due indirectly to decreases in glomerular
filtration rate, the glomerular sieving coefficient of
lysozyme, and impairment of tubular endocytic uptake
of lysozyme. The direct effect of aminoglycosides on
lysosomal protein degradation may be due to an in-
crease in intralysosomal pH and subsequent decrease in
the activity of proteolytic enzymes. Treatment of rats
with gentamicin decreased the lysosomal activity of
cathepsin B (11), a proteolytic enzyme responsible for
the lysosomal breakdown of egg white lysozyme (27).
Acute Effects of Gentamicin
Cationic LMWP such as lysozyme and cytochrome c
compete for anionic binding sites at the proximal tubule
brush border, the first step in endocytic tubular
reabsorption (1,28,29). Similar competition between
polyeationic aminoglycosides appears to take place in
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FIGURE 5. Dose-dependent inhibition of protein degradation by
gentamicin. Protein degradation was measured as the release of
trichloroacetic acid (TCA) soluble radioactivity from the slices into
the medium and expressed as percentage ofthe total radioactivity.
Bars represent mean ± SEM of values obtained from 4 rats.
Asterisk (*) denotes significantly different from control (p < 0.05).
From Cojocel et al. (26). Reprinted with permission ofthe Society
of Toxicology.
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FIGURE 6. Effect of aminoglycosides on protein degradation. Renal
degradation of lysozyme in control and aminoglycoside-treated
rats (30mg/kg/day) for 7 days. Values are represented as mean ± 1
SD of 5 or more kidneys. Asterisk (*) denotes significantly
different from control (p < 0.05). From Cojocel et al. (8).
Reprinted with permission of Academic Press.
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FIGURE 7. Effectofacuteexposuretogentamicin onthereabsorption
of lysozyme by the isolated perfused rat kidneys. C = control
kidneys. Bars represent mean ± SEM of 4 kidneys. Asterisk (*)
denotes significantly different from control (p < 0.05). From
Cojocel and Hook (32). Reprinted with permission of Elsevier
Scientific Publishers, Ireland, Ltd.
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FIGURE 8. Catabolism of RSI-lysozyme by isolated perfused rat
kidneys after acute exposure to gentamicin. Catabolism of
1251-lysozymewasmeasuredasreleaseofnonprecipitable '25I-radio-
activity by TCA (trichloroacetic acid) to the perfusate. Bars
represent mean ± SEM of 4 kidneys. Asterisk (*) denotes
significantly different from control (p < 0.05). From Cojocel and
Hook (32). Reprinted with permission of Elsevier Scientific
Publishers, Ireland, Ltd.
the processes of binding to the brush border (2) and
subsequent renal accumulation (30). Since renal
absorption oflysozyme takes place via endocytosis (31),
the pharmacological interaction between lysozyme and
gentamicin molecules in the early time after gentamicin
infusion is very likely to affect tubular reabsorption and
intracellular catabolism of lysozyme in the absence of
tubular damage.
Isolated rat kidneys were perfused with gentamicin
at concentrations of 0.25, 0.50, 1.0 and 2.5 mg/mL. A
dose-dependent decrease in percentage reabsorption of
lysozyme (Fig. 7) showed that gentamicin inhibits
tubular reabsorption of lysozyme in a dose-dependent
manner (32). Renal catabolism of 125I-lysozyme to
smaller degradation products was measured as non-
precipitable radioactivity (125I and 125I-monoiodotyro-
sine) released to the perfusate. Perfusion ofthe kidneys
at aperfusate concentration ofgentamicin of0.5 mg/mL
and higher induced almost complete inhibition of renal
degradation of lysozyme (Fig. 8). This inhibition could
be due primarily to inhibition oftubular reabsorption of
lysozyme by gentamicin (Fig. 7) and additionally to the
inhibition of enzymatic activity of lysosomal proteases
responsible for the lysosomal catabolism of lysozyme.
In summary, aminoglycosides act as nephrotoxicants
at the glomerulus, by reducing the glomerular filtration
of inulin and cationic proteins, at the tubule by inhibit-
ing the endocytic reabsorption, and at the lysosome,
by decreasing the proteolytic activity of lysosomal
enzymes.
We gratefully acknowledge the assistance of Diane Hummel and
Janet Dingerdissen in preparing the manuscript.
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